Memorial Sloan-Kettering’s Bach Balks At Drug Pricing
This article was originally published in The Pink Sheet Daily
Peter Bach slammed the industry over high drug prices and practices such as rebating, which he said confound open debate about drug cost and benefit, during a panel discussion at the BIO CEO & Investor conference.
You may also be interested in...
Sanofi’s recent reduction of the Zaltrap price after the Memorial Sloan-Kettering Cancer Center said it would not provide the drug to its advanced colorectal cancer patients due to its high cost relative to Avastin highlights the role cost and available clinical evidence will have as payers make value-based purchasing decisions.
COVID-19 disruptions, less favorable currency and the shadow of drug price reform could mean more headwinds for pharma during this S&E period after a strong Q2.
Congress is considering legislation that would reverse some of the Trump administration's friendly corporate tax policies, presenting another challenge to the biopharmaceutical industry.